PharmaTher Holdings Ltd. (PHRRF)
USD 0.16
(-0.62%)
USD 0.16
(-0.62%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 252.9 Thousand CAD | -71.66% |
| 2023 | 892.47 Thousand CAD | 170.19% |
| 2022 | 330.31 Thousand CAD | -8.51% |
| 2021 | 361.06 Thousand CAD | 3259.32% |
| 2020 | 10.74 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 251.7 Thousand CAD | -53.89% |
| 2024 Q2 | 545.82 Thousand CAD | -32.0% |
| 2024 Q1 | 802.66 Thousand CAD | -10.06% |
| 2024 Q4 | 252.9 Thousand CAD | 0.48% |
| 2023 Q2 | 325.63 Thousand CAD | 124.57% |
| 2023 Q3 | 563.25 Thousand CAD | 72.97% |
| 2023 Q4 | 892.47 Thousand CAD | 58.45% |
| 2023 Q1 | 145 Thousand CAD | -56.1% |
| 2023 FY | 892.47 Thousand CAD | 170.19% |
| 2022 Q4 | 330.31 Thousand CAD | -10.37% |
| 2022 Q3 | 368.53 Thousand CAD | -25.23% |
| 2022 Q2 | 492.9 Thousand CAD | 52.52% |
| 2022 Q1 | 323.17 Thousand CAD | -10.49% |
| 2022 FY | 330.31 Thousand CAD | -8.51% |
| 2021 Q1 | 339.57 Thousand CAD | 0.0% |
| 2021 FY | 361.06 Thousand CAD | 3259.32% |
| 2021 Q3 | 1.45 Million CAD | 478.26% |
| 2021 Q4 | 361.06 Thousand CAD | -75.26% |
| 2021 Q2 | 252.37 Thousand CAD | -25.68% |
| 2020 FY | 10.74 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.526% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 97.361% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.495% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.651% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.571% |
| Mesoblast Limited | 188.44 Million USD | 99.866% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 93.434% |
| Genus plc | 485 Million USD | 99.948% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 95.671% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 89.95% |
| Marizyme, Inc. | 26.67 Million USD | 99.052% |
| ContraFect Corporation | 32.53 Million USD | 99.223% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 93.345% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 87.236% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 93.393% |
| Intellipharmaceutics International Inc. | 12 Million USD | 97.894% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 97.853% |
| MultiCell Technologies, Inc. | 1617.67 USD | -15533.658% |
| Accustem Sciences Inc. | 1.07 Million USD | 76.567% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.673% |
| EV Biologics, Inc. | 2.11 Million USD | 88.043% |
| Q BioMed Inc. | 8.13 Million USD | 96.89% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.695% |
| Neon Bloom, Inc. | 1.22 Million USD | 79.375% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 95.086% |
| Biomind Labs Inc. | 1.49 Million USD | 83.124% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 99.896% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 98.626% |
| Skye Bioscience, Inc. | 14.07 Million USD | 98.203% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 87.419% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -77.98% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 97.328% |
| IMV Inc. | 37.93 Million USD | 99.333% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -25.749% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 95.599% |
| GB Sciences, Inc. | 5.41 Million USD | 95.332% |
| Alpha Cognition Inc. | 7.16 Million USD | 96.47% |
| HST Global, Inc. | 593.59 Thousand USD | 57.395% |
| CSL Limited | 18.62 Billion USD | 99.999% |
| Halberd Corporation | 728.71 Thousand USD | 65.295% |
| Enzolytics Inc. | 365.26 Million USD | 99.931% |
| Resverlogix Corp. | 67.39 Million USD | 99.625% |
| Affymax, Inc. | 8.87 Million USD | 97.149% |
| SYBLEU INC | 681.41 Thousand USD | 62.886% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 69.847% |
| argenx SE | 444.95 Million USD | 99.943% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.662% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 85.245% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 97.875% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 93.1% |
| AVAX Technologies, Inc. | 3.99 Million USD | 93.668% |
| Zenith Capital Corp. | 27.56 Thousand USD | -817.338% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.981% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -5.97% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 93.228% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 62.854% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.787% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 97.203% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -277.865% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 82.362% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.497% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 90.674% |
| BioStem Technologies, Inc. | 15.9 Million USD | 98.41% |
| ONE Bio Corp. | 27.49 Million USD | 99.08% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 45.577% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -821.886% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 79.916% |
| Agentix Corp. | 2.51 Million USD | 89.926% |
| LadRx Corporation | 2.2 Million USD | 88.507% |
| Cell Source, Inc. | 15.8 Million USD | 98.4% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -465.825% |
| Regen BioPharma, Inc. | 5.45 Million USD | 95.366% |
| Regen BioPharma, Inc. | 5.45 Million USD | 95.366% |
| NovAccess Global Inc. | 7.86 Million USD | 96.783% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 98.978% |
| Itoco Inc. | 1.65 Million USD | 84.702% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 87.673% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 95.819% |
| Kadimastem Ltd | 3.5 Million USD | 92.784% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 40.009% |
| CytoDyn Inc. | 127.89 Million USD | 99.802% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -505.041% |
| Mobile Lads Corp. | 1.31 Million USD | 80.746% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 83.854% |
| Qrons Inc. | 1.48 Million USD | 83.012% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 97.71% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 68.731% |
| Rebus Holdings, Inc. | 5.24 Million USD | 95.175% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 95.855% |
| International Stem Cell Corporation | 5.27 Million USD | 95.207% |
| Bioxytran, Inc. | 3.24 Million USD | 92.217% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 59.588% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 94.523% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.383% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 98.864% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 87.513% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 95.383% |
| Neutra Corp. | 973.52 Thousand USD | 74.022% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.128% |
| PureTech Health plc | 125.58 Million USD | 99.799% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 93.269% |
| IXICO plc | 1.9 Million USD | 86.691% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 98.768% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.755% |
| CSL Limited | 18.62 Billion USD | 99.999% |
| Cellectis S.A. | 249.36 Million USD | 99.899% |